Zydus Lifesciences Partners with Takeda to Launch Novel GERD Drug in India

Zydus Lifesciences announced a licensing agreement with Takeda Pharmaceutical to market Vonoprazan, a drug for gastroesophageal reflux disease (GERD), in India. Marketed under the brand name Vault, the drug is approved by the DCGI for treating reflux esophagitis and Acid Peptic Disorders (APD).

Zydus Lifesciences revealed on Wednesday its new licensing agreement with Takeda Pharmaceutical to introduce the drug Vonoprazan in India, targeting the treatment of gastroesophageal reflux disease (GERD).

Under this non-exclusive patent licensing agreement, Zydus will market the novel Potassium Competitive Acid Blocker (P-CAB) under the brand name Vault, the company announced in a statement.

'With a rich legacy in marketing gastrointestinal therapies in India, we have been offering different breakthrough clinical options across the spectrum,' said Zydus Lifesciences MD Sharvil Patel.

Vonoprazan has gained approval from the Drugs Controller General of India (DCGI) for the treatment of adults with reflux esophagitis and other Acid Peptic Disorders (APD).

(With inputs from agencies.)